Literature DB >> 10229627

Development of fluorine-18-labeled 5-HT1A antagonists.

L Lang1, E Jagoda, B Schmall, B K Vuong, H R Adams, D L Nelson, R E Carson, W C Eckelman.   

Abstract

We have synthesized five fluorinated derivatives of WAY 100635, N-{2-[4-(2-methoxyphenyl)piperazino]ethyl}-N-(2-pyridyl)cyclohe xaneca rboxamide (4a), using various acids in place of the cyclohexanecarboxylic acid (CHCA, 2a) in the reaction scheme. The five acids are 4-fluorobenzoic acid (FB, 2b), 4-fluoro-3-methylbenzoic acid (MeFB, 2c), trans-4-fluorocyclohexanecarboxylic acid (FC, 2d), 4-(fluoromethyl)benzoic acid (FMeB, 2e), and 3-nitro-4-(fluoromethyl)benzoic acid (NFMeB, 2f) (see Scheme 1). These compounds were radiolabeled with fluorine-18, and their biological properties were evaluated in rats and compared with those of [11C]carbonyl WAY 100635 ([carbonyl-11C]4a). [Carbonyl-11C]4a cleared the brain with a biological half-life averaging 41 min. The metabolite-corrected blood radioactivity had a half-life of 29 min. [18F]FCWAY ([18F]4d) gave half-lives and intercepts comparable to [carbonyl-11C]4a in the brain, but the blood clearance was faster. [18F]FBWAY ([18F]4b) showed an early rapid net efflux from the whole brain, clearing with a biological half-life of 35 min. The metabolite-corrected blood half-life was 41 min. The comparable whole brain and blood half-lives for Me[18F]FBWAY ([18F]4c) were 16 and 18 min, respectively. For each compound, the corresponding carboxylic acid was identified as a major metabolite in blood. Fluoride was also found after injection of [18F]4d. However, for all compounds there was a good correlation (R > 0.97) between the differential uptake ratio (DUR, (%ID/g) x body weight (g)/100) in individual rat brain regions at 30 min after injection and the concentration of receptors as determined by in vitro quantitative autoradiography in rat. Specific binding ratios [region of interest (ROI)/cerebellum-1] in control studies for cortex (Ctx) and hippocampus (H) were higher for [carbonyl-11C]4a and [18F]4d compared to [18F]4b and [18F]4c. [18F]4d has similar pharmacokinetic properties and comparable specific binding ratios to [carbonyl-11C]4a. Fifty nanomoles of 4a blocked only 30% of the specific binding of [18F]4d, while complete blockade was obtained from co-injection of 200 nmol of 4a (H/Cb-1 from 17.2 to 0.6). [18F]4b and [18F]4c showed lower specific binding ratios than [carbonyl-11C]4a and [18F]4d. [18F]4c was superior to [18F]4b since its specific binding was more readily blocked by 4a. These studies suggest that [18F]4c should be a useful compound to assess dynamic changes in serotonin levels while [18F]4d, with its high contrast and F-18 label, should provide better statistics and quantification for static measurement of 5-HT1A receptor distribution.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229627     DOI: 10.1021/jm980456f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates.

Authors:  Nicolas Tournier; Salvatore Cisternino; Marie-Anne Peyronneau; Sébastien Goutal; Frédéric Dolle; Jean-Michel Scherrmann; Michel Bottlaender; Wadad Saba; Héric Valette
Journal:  Pharm Res       Date:  2012-05-30       Impact factor: 4.200

2.  An automated one-step one-pot [(18)F]FCWAY synthesis: development and minimization of chemical impurities.

Authors:  Bik-Kee Vuong; Dale O Kiesewetter; Lixin Lang; Ying Ma; William C Eckelman; Michael A Channing
Journal:  Nucl Med Biol       Date:  2007-05       Impact factor: 2.408

3.  Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression.

Authors:  Allison C Nugent; Earle E Bain; Paul J Carlson; Alexander Neumeister; Omer Bonne; Richard E Carson; William Eckelman; Peter Herscovitch; Carlos A Zarate; Dennis S Charney; Wayne C Drevets
Journal:  Eur Neuropsychopharmacol       Date:  2013-02-20       Impact factor: 4.600

4.  5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction.

Authors:  Giampiero Giovacchini; Maria T Toczek; Robert Bonwetsch; Anto Bagic; Lixin Lang; Charles Fraser; Pat Reeves-Tyer; Peter Herscovitch; William C Eckelman; Richard E Carson; William H Theodore
Journal:  J Nucl Med       Date:  2005-07       Impact factor: 10.057

5.  Distribution of the 5-HT(1A) receptor antagonist [ (18)F]FPWAY in blood and brain of the rat with and without isoflurane anesthesia.

Authors:  Joji Tokugawa; Laura Ravasi; Toshiyuki Nakayama; Lixin Lang; Kathleen C Schmidt; Jurgen Seidel; Michael V Green; Louis Sokoloff; William C Eckelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-22       Impact factor: 9.236

Review 6.  Measuring serotonin synthesis: from conventional methods to PET tracers and their (pre)clinical implications.

Authors:  Anniek K D Visser; Aren van Waarde; Antoon T M Willemsen; Fokko J Bosker; Paul G M Luiten; Johan A den Boer; Ido P Kema; Rudi A J O Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-27       Impact factor: 9.236

7.  Automated radiochemical synthesis of [18F]FBEM: a thiol reactive synthon for radiofluorination of peptides and proteins.

Authors:  Dale O Kiesewetter; Orit Jacobson; Lixin Lang; Xiaoyuan Chen
Journal:  Appl Radiat Isot       Date:  2010-10-08       Impact factor: 1.513

8.  Using cerebral white matter for estimation of nondisplaceable binding of 5-HT1A receptors in temporal lobe epilepsy.

Authors:  Giampiero Giovacchini; Shielah Conant; Peter Herscovitch; William H Theodore
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

Review 9.  Serotonin-1A receptor imaging in recurrent depression: replication and literature review.

Authors:  Wayne C Drevets; Michael E Thase; Eydie L Moses-Kolko; Julie Price; Ellen Frank; David J Kupfer; Chester Mathis
Journal:  Nucl Med Biol       Date:  2007-10       Impact factor: 2.408

10.  Application of highly sensitive UPLC-MS to determine biodistribution at tracer doses: validation with the 5-HT1A ligand [(18)F]FPWAY.

Authors:  Ying Ma; Lixin Lang; Larry Reyes; Joji Tokugawa; Elaine M Jagoda; Dale O Kiesewetter
Journal:  Nucl Med Biol       Date:  2009-03-26       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.